Measurements of Doppler Signals Noninvasively From the Lung in Congestive Heart Failure

Pulmonary Edema Clinical Trial

Official title:

Evaluation of Lung Doppler Signals in Congestive Heart Failure(CHF)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01940328
• Other study ID #: DOP13
• Status: Completed
• Phase: N/A
• First received: September 9, 2013
• Last updated: February 7, 2017
• Start date: October 2013
• Est. completion date: March 2016

Study information

• Verified date: August 2013
• Source: Echosense Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The purpose of this study is to evaluate the lung Doppler signals in left HF patients with and without pulmonary congestion (i.e. decompensated left HF patients and compensated left HF patients respectively), in comparison to a control group of subjects without CHF (non-CHF controls), in order to determine the diagnostic value of this non-invasive method in CHF. If this method will prove to be of diagnostic value, it could potentially be used to diagnose and monitor CHF patients in both inpatient and outpatient settings.

Description:

Study Participants A total of 150 patients will be recruited for this study over a span of 18 months.

Patients will be divided into 3 subgroups:

1. Acute decompensated left heart failure- Patients are eligible for enrollment if they presented to the emergency department within the previous few hours with acute pulmonary congestion or pulmonary edema, diagnosed on the basis of all of the following criteria:

1. Dyspnea at rest or with minimal activity

2. Rales on auscultation

3. Evidence of pulmonary congestion or edema on chest X-ray.

4. BNP level >400 pg/ml This subgroup will be recruited in the emergency medicine department (EMD) following initial treatment and stabilization.

2. Compensated left heart failure - Patients with significant stable left HF (NYHA II-III) who are on optimal medical treatment for CHF and are without clinical or laboratory evidence of pulmonary congestion (i.e. patients without dyspnea at rest, without rales on auscultation and with BNP levels < 100 pg/ml). This subgroup will be recruited among inpatients and/or outpatients at the Rambam campus.

3. Non-CHF controls (patients without CHF and without uncontrolled hypertension). This subgroup will be recruited among inpatients and/or outpatients at the Rambam health care campus.

Study measurements

For the compensated left HF patients and the non-CHF controls, measurements will be done once following inclusion.

For the decompensated left HF patients, several measurements will be conducted, both following inclusion (at the EMD) and each day during hospitalization (at the internal medicine department).

Measurements following inclusion:

Following informed consent and applying the inclusion and exclusion criteria, all eligible patients will undergo physical examination including weight, vital signs (blood pressure, heart rate, respiratory rate, O2 saturation by pulse oximetry) and a full assessment of CHF status by physical examination (lung auscultation, assessment of leg edema, weight, JVP etc.). (See figure 2). An ECG recording will be performed and a blood test for BNP will be drawn for all patients.

For the assessment of dyspnea, decompensated left HF patients will be asked to indicate their level of dyspnea on a visual analogue scale (3) and/or a 7-points categorical Likert scale (4).

Chest X-ray: Decompensated patients will undergo chest X ray (CXR) as part of the regular evaluation in the EMD. The 2 other subgroups will undergo CXR only if a recent CXR (<6 months) is not available, or if clinically indicated.

Echocardiography: an attempt will be made to perform echocardiography in the EMD for all decompensated patients who are in sinus rhythm, including a full diastolic assessment. However, due to the limited availability of the echocardiography service, not all patients will undergo echo at the EMD and therefore this examination is considered optional.

A recent (<6 months) echocardiography is required for the 2 other subgroups. If a recent echo is not available, a new one will be done as close as possible to inclusion.

Lung Doppler signals will be recorded in sitting position from selected locations over the right chest wall. If the subject is unable to sit in a chair, the headrest of the patient's bed will be tilted upwards to about 45 degrees. Regarding the decompensated left HF patients, the first measurement of LDS will take place as soon as possible after admission to the emergency medicine department, providing the patient has been adequately treated and stabilized and is willing and able to sign an informed consent form. The LDS measurement will be repeated twice more at the EMD at 1 hour intervals. LDS will be recorded only once for the compensated patients and the non-CHF controls.

Follow up measurements during hospitalization (decompensated patients only) During their hospital stay in the internal medicine department, decompensated left HF patients will repeat part of the former study measurements.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: March 2016
• Est. primary completion date: December 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age over 18 years

2. Belongs to one of the following categories:

A. Acute decompensated left HF: patients with acute pulmonary congestion or pulmonary edema diagnosed on the basis of all of the following criteria:

1. Dyspnea at rest or with minimal activity

2. Rales on auscultation

3. Evidence of pulmonary congestion or edema on chest X-ray.

4. BNP level >400 pg/ml

B. Compensated left HF: patients with significant stable left HF (NYHA II-III) who are on optimal medical treatment for CHF, and are without clinical or laboratory evidence of pulmonary congestion. The following 3 criteria must be met:

1. No dyspnea at rest

2. No rales on auscultation

3. BNP levels < 100 pg/ml

C. Non-CHF controls: patients without CHF and without uncontrolled hypertension.

3 Signed Informed Consent

Exclusion Criteria:

• Decompensated left HF subgroup & Non CHF controls

1. Pneumonia- currently or in the past 1 month prior to inclusion

2. Non-cardiogenic pulmonary edema or lung injury (e.g. ARDS)

3. Interstitial lung disease

4. Severe kyphosis, scoliosis or chest wall deformity

5. Pregnant women

Compensated left HF subgroup

1. Chronic obstructive pulmonary disease (COPD)

2. Asthma

3. Interstitial lung disease

4. Any other obstructive or restrictive lung diseases

5. Pneumonia- currently or in the past 3 months prior to inclusion

6. Non-cardiogenic pulmonary edema or lung injury (e.g. ARDS)

7. Current or past pulmonary embolism

8. Large right sided pleural effusion

9. Severe kyphosis, scoliosis or chest wall deformity

10. Pregnant woman

Related Conditions & MeSH terms

• Heart Failure
• Pulmonary Edema

Intervention

Device:
• Transchoracic ultrasound Doppler

Locations

Country	Name	City	State
Israel	EMD Rambam Hospital	Haifa

Sponsors (1)

Lead Sponsor	Collaborator
Echosense Ltd.

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Diagnose specific pattern of LDS in patients by features as velocity, power etc in comparison to controls		1.5y to collect all data and obtain a diagnostic pattern